- Trials with a EudraCT protocol (180)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (39)
180 result(s) found for: Herpes.
Displaying page 9 of 9.
EudraCT Number: 2008-007478-39 | Sponsor Protocol Number: 42160443NPP2001 | Start Date*: 2009-10-07 | |||||||||||||||||||||
Sponsor Name:Janssen Cilag International, NV | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-T... | |||||||||||||||||||||||
Medical condition: Postherpetic Neuralgia and Post-Traumatic Neuralgia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001038-17 | Sponsor Protocol Number: MK-8228-040 | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in ... | |||||||||||||
Medical condition: Cytomegalovirus (CMV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Prematurely Ended) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002676-14 | Sponsor Protocol Number: B7921023 | Start Date*: 2020-08-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A 24-WEEK RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF 06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN P... | |||||||||||||
Medical condition: Rheumatoid arthritis (RA) is a chronic, autoimmune disease characterized by joint inflammation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) HU (Completed) SK (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001253-32 | Sponsor Protocol Number: HZNP-HZN-825-303 | Start Date*: 2022-02-16 | |||||||||||
Sponsor Name:Horizon Therapeutics Ireland DAC | |||||||||||||
Full Title: A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GR (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002609-24 | Sponsor Protocol Number: LESVIPREGA/20/P3-3 | Start Date*: 2021-05-17 | |||||||||||
Sponsor Name:Laboratorios Lesvi, S.L. (Neuraxpharm group) | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Clinical Study to Evaluate Efficacy and Safety of the Once-Daily Extended-Release Pregabalin and the Immediate-Release Pregabali... | |||||||||||||
Medical condition: Peripheral neuropathic pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) HU (Completed) BG (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000706-34 | Sponsor Protocol Number: A3921237 | Start Date*: 2014-10-06 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (C... | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015496-27 | Sponsor Protocol Number: Etoricox09-10 | Start Date*: 2010-03-15 | |||||||||||||||||||||||||||||||
Sponsor Name:BG university hospital Bergmannsheil GmbH | |||||||||||||||||||||||||||||||||
Full Title: Wirksamkeit von Etoricoxib bei Patienten mit neuropathischen Schmerzen mit und ohne peripherer Hyperalgesie (Efficacy of etoricoxibe in patients with neuropathic pain with and without peripheral hy... | |||||||||||||||||||||||||||||||||
Medical condition: Animal experiments analysing anti-hyperalgesic effects of Coxibs show inconsistent results due to different used dosages and varying different pain models. Theoretical the use of NSAIDs is rational... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002977-24 | Sponsor Protocol Number: 209538 | Start Date*: 2019-04-03 | |||||||||||
Sponsor Name:GlaxoSmithKline S.A. | |||||||||||||
Full Title: A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to... | |||||||||||||
Medical condition: Healthy volunteers (chronic obstructive pulmonary disorder [COPD])) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FI (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000853-29 | Sponsor Protocol Number: TRACE | Start Date*: 2020-01-14 | ||||||||||||||||||||||||||
Sponsor Name:Klinikum der Universität München | ||||||||||||||||||||||||||||
Full Title: Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial | ||||||||||||||||||||||||||||
Medical condition: Chemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003450-22 | Sponsor Protocol Number: P-105-303 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standar... | |||||||||||||
Medical condition: AdV infection in pediatric and adult allo HCT recipients receiving standard of care | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000831-21 | Sponsor Protocol Number: HZNP-DAX-202 | Start Date*: 2023-02-06 | |||||||||||
Sponsor Name:Horizon Therapeutics Ireland DAC | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF DAXDILIMAB SUBCUTANEOUS INJECTION IN REDUCING DISEASE ACTIVITY I... | |||||||||||||
Medical condition: Discoid Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000411-10 | Sponsor Protocol Number: 4478944789 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||||||||||||
Sponsor Name:BG-Kliniken Bergmannsheil, Dept. of Pain Management | |||||||||||||||||||||||||||||||||
Full Title: Effects of Pregabalin on mechanical hyperalgesia - EPOM | |||||||||||||||||||||||||||||||||
Medical condition: patients with pain for at least 6 months and hyperalgesia with one of the following diagnoses: peripheral nerve lesion, plexus lesion, radicular lesion, spinal lesion, polyneuropathy, postzosteric ... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010551-26 | Sponsor Protocol Number: D0102C00003 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a S... | |||||||||||||
Medical condition: Phase I part of the study: Solid tumours that are refractory to standard therapies Phase II part of the study: trastuzumab- or lapatinib-ineligible patients with locally advanced (not amenable to s... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) HU (Completed) SE (Completed) FR (Completed) IT (Completed) BG (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024247-32 | Sponsor Protocol Number: 1263-203 | Start Date*: 2012-03-09 | ||||||||||||||||
Sponsor Name:VIROPHARMA INCORPORATED | ||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WH... | ||||||||||||||||||
Medical condition: CMV INFECTIONS IN TRANSPLANT RECIPIENTS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) ES (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000242-38 | Sponsor Protocol Number: BEL114674 | Start Date*: 2013-01-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy | |||||||||||||
Medical condition: Idiopathic Membranous Nephropathy (IMN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004784-58 | Sponsor Protocol Number: MRI-0143 | Start Date*: 2007-06-22 | |||||||||||
Sponsor Name:University of Leuven | |||||||||||||
Full Title: Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005264-86 | Sponsor Protocol Number: 1182.98 | Start Date*: 2007-02-21 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p... | ||
Medical condition: The objective of this study is to demonstrate the safety and efficacy of TPV/r among a racially diverse HIV-positive population of females and males who are three-class (NRTI, NNRTI, and PI) experi... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001577-24 | Sponsor Protocol Number: NI-0501-14 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AG (Sobi AG) | |||||||||||||
Full Title: A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage ac... | |||||||||||||
Medical condition: Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD). MAS in the context of pediatric and adult Systemic lup... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) IT (Trial now transitioned) PL (Completed) DE (Completed) CZ (Trial now transitioned) BE (Completed) SE (Completed) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002438-12 | Sponsor Protocol Number: MRV01C | Start Date*: 2007-09-21 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur MSD S.N.C. | |||||||||||||||||||||||
Full Title: An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) whe... | |||||||||||||||||||||||
Medical condition: Combined Measles, Mumps, Rubella and Varicella Live Vaccine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) GR (Completed) NL (Not Authorised) DK (Completed) SE (Completed) ES (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005023-33 | Sponsor Protocol Number: 1182.99 | Start Date*: 2007-03-15 | |||||||||||
Sponsor Name:Boehringer Ingelheim France SAS | |||||||||||||
Full Title: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... | |||||||||||||
Medical condition: Treatment with three-class (NRTI, NNRTI, and PI) experienced HIV positive patients with HCV or HBV co-infection, with a minimum of 3-months duration for each class and have documented resistance to... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
